View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 27, 2019

Fresenius Medical Care closes $2bn NxStage Medical acquisition

German dialysis products and services company Fresenius Medical Care has completed the $2bn acquisition of US-based medical devices maker NxStage Medical, after receiving clearance from the US antitrust authorities.

German dialysis products and services company Fresenius Medical Care has completed the $2bn acquisition of US-based medical devices maker NxStage Medical , after receiving clearance from the US antitrust authorities.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NxStage Medical primarily focuses on the development, production and marketing of medical devices for in-home dialysis and critical care.

The deal, first announced in August 2017, will help Fresenius Medical Care leverage its manufacturing, supply chain and marketing capabilities across the dialysis products, services and Care Coordination businesses.

NxStage Medical ’s portfolio includes the portable haemodialysis system called NxStage System One, which has been cleared by the US Food and Drug Administration (FDA) for home use.”

Fresenius Medical Care CEO Rice Powell said: “By combining NxStage’s capabilities with our broad product and service offering, we can help patients to live even more independently.

“In addition to broadening our product portfolio, this acquisition positions Fresenius Medical Care to benefit from the growing trend toward home-based therapies.”

Founded in 1998, NxStage Medical employs nearly 3,800 people globally. The company generated $394m in revenue in 2017.

Its portfolio includes the portable haemodialysis system called NxStage System One, which has been cleared by the US Food and Drug Administration (FDA) for home use.

Commenting on the deal, Fresenius Medical Care North America CEO Bill Valle noted: “With their strong culture of innovation and transformation, they will help us to realise our vision of delivering access to superior patient care and outcomes in a lower-cost-of-care home setting to all the patients we care for.”

Recently, medical products firm B. Braun Medical acquired the Medisystems Streamline Bloodlines business of NxStage Medical for an undisclosed amount.

The acquired products include Streamline Bloodline for Dialog+ haemodialysis system and the Fresenius Medical Care haemodialysis system, along with the Streamline Bloodline Long for the Fresenius Medical Care haemodialysis system.

This addition of Streamline bloodline products expands B. Braun Medical’s dialysis products portfolio.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network